Understanding the Antigen Composition of COVID-19 Vaccines
The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has recommended retaining the current COVID-19 vaccine antigen composition, specifically a monovalent XBB.1.5, due to the broad immune responses demonstrated against circulating variants. The group advises further data collection on immune responses and vaccine effectiveness, as well as strengthened surveillance to monitor the antigenic distinctness of emerging variants. The TAG-CO-VAC also encourages the development of vaccines that can improve protection against infection and reduce transmission of SARS-CoV-2.